Update on Percutaneous Ablation for Sarcoma.
Curr Oncol Rep
; 26(6): 601-613, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38647995
ABSTRACT
PURPOSE OF REVIEW To provide an update on the current state of percutaneous thermal ablation in the treatment of sarcoma. RECENT FINDINGS:
Data continue to accrue in support of ablation for local control and palliation of specific sarcoma subtypes such as extra-abdominal desmoid fibromatosis and for broader indications such as the treatment of oligometastatic disease. The synergistic possibilities of various combination therapies such as cryoablation and immunotherapy represent intriguing areas of active investigation. Histotripsy is an emerging non-invasive, non-thermal ablative modality that may further expand the therapeutic arsenal for sarcoma treatment. Percutaneous thermal ablation is a valuable tool in the multidisciplinary management of sarcoma, offering a minimally invasive adjunct to surgery and radiation therapy. Although there remains a paucity of high-level evidence specific to sarcomas, ablation techniques are demonstrably safe and effective for achieving local tumor control and providing pain relief in select patients and are of particular benefit in those with metastatic disease or requiring palliative care.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Sarcoma
Límite:
Humans
Idioma:
En
Revista:
Curr Oncol Rep
/
Curr. oncol. rep
/
Current oncology reports
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos